CD274 and adrenal cortex carcinoma: On the other hand ACC show a weak to no programmed death ligand-1 (PD-L1) expression [6], a decisive biomarker for the use of Pembrolizumab in head and neck squamous cell carcinoma, which makes the benefit from immune checkpoint inhibitors questionable.